Conditions: Rheumatoid Arthritis
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate quality of life changes in Puerto Rican subjects with Rheumatoid Arthritis treated with Humira (adalimumab) as their first Anti-TNF Monoclonal Antibody.

Detailed description:

Arms:
arm 1: All subjects will receive Adalimumab

Interventions: intervention 1: Humira (adalimumab)
Intervention descriptions: intervention 1: 40 mg eow

Protocol document: